Who owns CONTEXT THERAPEUTICS INC COM?
- Ticker: CNTX
- CUSIP Number: 21077p108
Tip: Access positions for across all investors
Analyze quarterly positions in Context Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Context Therapeutics stock
Who bought or sold CONTEXT THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| MPM Oncology Impact Management | 11M | $28M | 0% | Mar 2026 |
|
| Blue Owl Capital Holdings | 7.4M | $11M | 0% | Dec 2025 |
|
| Nextech Invest | 7.4M | $19M | 0% | Mar 2026 |
|
| Deep Track Capital | 7.4M | $19M | 0% | Mar 2026 |
|
| Soleus Capital Management | 7.0M | $18M | 100% | Mar 2026 |
|
| Octagon Capital Advisors | 5.3M | $14M | 100% | Mar 2026 |
|
| Avidity Partners Management | 5.0M | $13M | -9% | Mar 2026 |
|
| Franklin Resources | 3.8M | $10M | -5% | Mar 2026 |
|
| Vanguard Group | 3.8M | $5.6M | 8% | Dec 2025 |
|
| Vanguard Capital Management | 3.4M | $9.0M | 100% | Mar 2026 |
|
| TCG Crossover Management | 2.7M | $7.0M | 100% | Mar 2026 |
|
| Marshall Wace | 2.6M | $3.8M | 7154% | Dec 2025 |
|
| Dr. Jeffrey R. Jay, M.D. | 2.2M | $5.9M | -52% | Mar 2026 |
|
| Millennium Management | 1.4M | $3.7M | -45% | Mar 2026 |
|
| Sio Capital Management | 1.3M | $2.0M | 0% | Dec 2025 |
|
| Squadron Capital Management | 1.1M | $2.9M | 100% | Mar 2026 |
|
| BlackRock | 847k | $2.2M | 0% | Mar 2026 |
|
| Geode Capital Management | 604k | $1.6M | -1% | Mar 2026 |
|
| Cormorant Asset Management | 530k | $1.4M | 100% | Mar 2026 |
|
| Renaissance Technologies | 508k | $747k | 59% | Dec 2025 |
|
| Jane Street | 437k | $1.1M | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 351k | $920k | 0% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 341k | $894k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 287k | $753k | 100% | Mar 2026 |
|
| Woodline Partners | 250k | $655k | 100% | Mar 2026 |
|
| Seven Fleet Capital Management | 191k | $500k | 100% | Mar 2026 |
|
| State Street Corporation | 166k | $243k | 9% | Dec 2025 |
|
| Citadel Advisors | 140k | $367k | 307% | Mar 2026 |
|
| HighTower Advisors | 126k | $331k | 0% | Mar 2026 |
|
| Bank of America Corporation | 115k | $301k | 100% | Mar 2026 |
|
| Pathstone Holdings | 110k | $289k | 0% | Mar 2026 |
|
| Hrt Financial | 105k | $275k | 100% | Mar 2026 |
|
| Mill Creek Capital Advisors | 105k | $154k | 0% | Dec 2025 |
|
| XTX Topco | 102k | $149k | 859% | Dec 2025 |
|
| Velan Capital Investment Management | 100k | $147k | 0% | Dec 2025 |
|
| Clear Harbor Asset Management | 93k | $243k | 0% | Mar 2026 |
|
| Northern Trust | 84k | $124k | 27% | Dec 2025 |
|
| Winton Capital | 81k | $213k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 81k | $211k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 61k | $161k | 100% | Mar 2026 |
|
| Point72 Asset Management | 57k | $150k | 9% | Mar 2026 |
|
| Quadrature Capital | 46k | $68k | 100% | Dec 2025 |
|
| Virtu Financial | 29k | $43k | 100% | Dec 2025 |
|
| CI Private Wealth | 27k | $70k | 76% | Mar 2026 |
|
| Advisor Group Holdings | 26k | $38k | 0% | Dec 2025 |
|
| HPM Partners | 20k | $52k | 0% | Mar 2026 |
|
| Sanctuary Advisors | 19k | $51k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 13k | $33k | 100% | Mar 2026 |
|
| Two Sigma Securities | 13k | $33k | 100% | Mar 2026 |
|
| Citigroup | 12k | $32k | 100% | Mar 2026 |
|
| Tower Research Capital | 9.6k | $14k | 100% | Dec 2025 |
|
| Morgan Stanley | 9.1k | $24k | 100% | Mar 2026 |
|
| UBS Group | 6.2k | $16k | 1163% | Mar 2026 |
|
| FNY Investment Advisers | 6.0k | $15k | 100% | Mar 2026 |
|
| Strive Financial Group | 1.7k | $4.0k | 0% | Mar 2026 |
|
| Farther Finance Advisors | 1.5k | $4.0k | 0% | Mar 2026 |
|
| SBI Securities | 78.00 | $204.001200 | -32% | Mar 2026 |
|
Who sold out of Context Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Blackstone Group | Dec 2025 | 2.4M | $3.6M |
| Alyeska Investment Group | Dec 2025 | 1.7M | $2.4M |
| Affinity Asset Advisors | Sep 2025 | 403k | $390k |
| Walleye Trading Advisors | Dec 2025 | 133k | $195k |
| Qube Research & Technologies | Sep 2025 | 82k | $80k |
| Nantahala Capital Management | Dec 2025 | 38k | $56k |
| Susquehanna International | Sep 2025 | 22k | $21k |
| Caxton | Dec 2025 | 18k | $27k |
| Barclays | Sep 2025 | 167.00 | $162.006700 |